FDA approves The Medicines Company’s ORBACTIV to treat ABSSSIs
ORBACTIV is the first and only antibiotic approved by FDA to treat ABSSSIs with a single, once-only administration. Once fully infused over three hours, the ORBACTIV treatment regimen
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
Streptococcus pneumonia (pneumococcus) is a gram-positive, alpha-hemolytic, aerotolerant, aerobic member of the genus Streptococcus. Currently, Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) is approved for adults in
The studies were conducted by Professor Paul Quax, Ph.D., and Yaƫl Nossent, Ph.D., of the Department of Surgery, Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center